Validation and refinement of survival models for liver retransplantation
Article first published online: 30 DEC 2003
Copyright © 2003 American Association for the Study of Liver Diseases
Volume 38, Issue 2, pages 460–469, August 2003
How to Cite
Rosen, H. R., Prieto, M., Casanovas-Taltavull, T., Cuervas-Mons, V., Guckelberger, O., Muiesan, P., Strong, R. W., Bechstein, W. O., O'Grady, J., Zaman, A., Chan, B., Berenguer, J., Williams, R., Heaton, N. and Neuhaus, P. (2003), Validation and refinement of survival models for liver retransplantation. Hepatology, 38: 460–469. doi: 10.1053/jhep.2003.50328
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- Manuscript Accepted: 12 MAY 2003
- Manuscript Received: 18 DEC 2002
- American College of Gastroenterology Clinical Research Award and a VA merit review grant, Washington, DC (to H.R.R.).
Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72%, 68%, and 36%, respectively (P < .0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P = .004). Utilizing both patient cohorts (n = 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model χ2 = 105, P < .0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted.